Jupiter Neurosciences has launched a new line of supplements called Nugevia, which feature a micellar resveratrol ingredient called Jotrol. The launch is a strategy for the company to generate near-term revenue while maintaining momentum in its pipeline of clinical research to develop pharmaceutical products for central nervous system disorders.

Jotrol’s micellar delivery technology is evidenced to offer a clinical-grade version of resveratrol which is nine times more available than resveratrol in standard forms, according to the company.

“The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” said Christer Rosén, chairman and CEO of Jupiter Neurosciences. “By building on the same proprietary technology platform that underpins our prescription drug development, we’re delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.”

Nugevia’s first three formulations target mitochondrial support, mental clarity, and beauty from within, and will be sold on a direct-to-consumer basis starting this year. The company also includes synergistic compounds in its formulations to enhance cellular resilience, support blood-brain barrier delivery, and more.

“We cracked the code on resveratrol’s widely published issue with bioavailability, and now we’re unlocking its potential beyond the clinic,” said Rosén. “Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.”

“Nugevia represents more than a product launch, it’s a strategic pipeline for growth,” Rosén continued. “By leveraging our core science in a consumer format, we’re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It’s smart capital allocation with real scientific impact.”